Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.
Frontiers in Pharmacology, 27 November 2023.
A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine
Frontiers in Pharmacology, 28 September 2023.
Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial
eClinicalMedicine, February 2023.
Pharmacokinetic and Pharmacodynamic Interaction of the Ayahuasca Constituents Harmine and Dimethyltryptamine (DMT) in the Rat Brain
OSF Preprints, 10 December 2022.
Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
PLOS Global Public Health, 16 November 2022.
Dexmedetomidine in Psychiatry: Repurposing of its Fast-Acting Anxiolytic, Analgesic and Sleep Modulating Properties
Pharmacopsychiatry, 16 November 2022.
Psychedelic Medicines: A Paradigm Shift from Pharmacological Substitution Towards Transformation-Based Psychiatry
Ayahuasca Healing and Science, 16 April, 2021.
Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers
Journal of Affective Disorders Reports, April 2021.
Impaired glutamate homeostasis in the nucleus accumbens in human cocaine addiction
Molecular Psychiatry, 28 June 2020.
Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat
Scientific Reports, 24 October 2019.
Effect of psilocybin on empathy and moral decision-making
International Journal of Neuropsychopharmacology, 1 September 2017.
Co-localised structural and functional changes in cocaine users are associated with recent cocaine consumption and potentially reversible
European Neuropsychopharmacology, 1 October, 2015.
Glutamatergic and neurometabolic alterations in chronic cocaine users measured with 1H‐magnetic resonance spectroscopy
Addiction Biology, 30 December 2014
FMR1 and mGluR5 as prospective molecular markers of sleep need in humans
Current Neuropharmacology, January 2014.
Prediction Of Psilocybin Response in Healthy Volunteers
PLOS ONE, 17 February 2012.
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Nature Reviews Neuroscience, 18 August 2010.
Reduced feed-back related negativity is associated with reinforcement-learning deficits in cocaine dependent patients
European Neuropsychopharmacology, August 2010.
2024
Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation
Scientific Reports, 26 March 2024
2023
Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.
Frontiers in Pharmacology, 27 Nov 2023.
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Frontiers in Pharmacology, 3 April 2023.
2022
Predicting Antidepressant Effects of Ketamine: the Role of the Pregenual Anterior Cingulate Cortex as a Multimodal Neuroimaging Biomarker
International Journal of Neuropsychopharmacology, 12 December, 2022
Acute effects of ketamine on the pregenual anterior cingulate: linking spontaneous activation, functional connectivity, and glutamate metabolism
European Achieves of Psychiatry and Clinical Neuroscience, 12 January 2022.
2021
A novel bedtime pulsatile-release caffeine formula ameliorates sleep inertia symptoms upon awakening
Scientific Reports, 5 October 2021.
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans
Molecules, 22 April 2021.
Comparison of Four fMRI Paradigms Probing Emotion Processing
Brain Sciences, 21 April 2021.
Towards Extending the Detection Window of Gamma-Hydroxybutyric Acid—An Untargeted Metabolomics Study in Serum and Urine Following Controlled Administration in Healthy Men
Metabolites, 12 March 2021.
Comparative phenomenology and neurobiology of meditative and psychedelic states of consciousness: Implications for psychedelic-assisted therapy
Handbook of medical hallucinogens, 2021.
Disorders due to use of hallucinogens
Reference Mental Health Disorders, 2021.
2019
Nocturnal gamma-hydroxybutyrate reduces cortisol awakening response and morning tryptophan catabolites in healthy volunteers
International Journal of Neuropsychopharmacology, 3 September 2019.
Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects
NeuroImage, 1 August 2019.
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine
European Neuropsychopharmacology, 19 April 2019.
Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring
European Neuropsychopharmacology, 19 April 2019.
Neurophysiological signature of gamma-hydroxybutyrate augmented sleep in healthy volunteers may reflect biomimetic sleep enhancement
Neuropsychopharmacology, 8 April 2019.
Comparing mental health across distinct groups of users of psychedelics, MDMA, psychostimulants, and cannabis
Journal of Psychoactive Drugs, 6 March, 2019.
2018
Positive psychology in the investigation of psychedelics and entactogens: A critical review
Neuropharmacology, 23 November 2018.
Gamma-hydroxybutyrate increases brain resting-state functional connectivity of the salience network and dorsal nexus in humans
NeuroImage, 30 March, 2018.
2016
Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
Psychological and Cognitive Sciences, 18 April 2016.
Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network
Social Cognitive Affective Disorder Neuroscience, 13 April 2016.
Effects of ketamine on cognition-emotion interaction in the brain
NeuroImage, 1 January 2016.
Serotonergic hallucinogen-induced visual perceptual alterations
Behavioural Neurobiology of Psychedelic Drugs, 2016.
2015
Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers
Biological Psychiatry, 15 October 2015
Unveiling metabolic alterations within the human reward circuitry in addiction by using a novel small-voxel, 1H-MRS (spectroscopy) protocol in the nucleus accumbens
European Neuropsychopharmacology, 1 October, 2015.
The 5-HT2A/1A agonist psilocybin reduces social pain and enhances empathy in healthy volunteers
European Neuropsychopharmacology, 1 October 2015
Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations
Psychopharmacology, 1 August 2015
The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing
European Neuropsychopharmacology, 1 April 2015
Chronic cocaine use is associated with glutamatergic and other neurometabolic alterations: a proton magnetic resonance spectroscopy study
Suchttherapie, 2015.
Exploring the antidepressant effects of ketamine: Insights from multimodal neuroimaging
ETH Zurich Research Collection, 2015
2014
A role for mGluR5-mediated signaling in regulating neurophysiological markers of sleep homeostasis in humans
Journal of Sleep Research, September 2014.
Multimodal PET-MRS Investigation of Glutamate-Dependent Neuroreceptor Plasticity in the Healthy Human Brain
Joint Annual Meeting ISMRM-ESMRMB, May 2014
2013
Modeling ketamine effects on synaptic plasticity during the mismatch negativity
Cerebral Cortex, 8 August 2013.
A Trip Out of Depression
Scientific American Mind, April 2013
The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions
Psychopharmacology, January 2013
2012
Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action
PLOS ONE, 24 September 2012.
Neurophysiological studies of psilocybin-induced hallucinations: role of 5-HT2A receptors
International Journal of Neuropsychopharmacology, June 2012.
Psilocybin Biases Facial Recognition, Goal-Directed Behavior, And Mood State Toward Positive Relative To Negative Emotions Through Different Serotonergic Subreceptors
Biological Psychiatry, 14 May 2012.
2011
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Journal of Psychopharmacology, November 2011.
The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations
Biological Psychiatry, 1 March 2011.
Acute ketamine administration modulates glutamatergic neurotransmission and functional brain activation in prefrontal cortex implications for major depression
Pharmacopsychiatry, 2011.
2010
The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations
Biological Psychiatry, 3 December 2010.
2008
Effects of the hallucinogenic 5-HT2A agonist psilocybin on object completion in humans
International Journal of Psychophysiology, September 2008